National Securities Initiates Coverage on Anadys Pharmaceuticals (ANDS) with a Buy
More News related to ANDS
- Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
More News related to New Coverage
- SEI (SEIC) Enters Multi-Year Agreement with Evercore Trust to Provide Back-Office Services
- Cisco (CSCO) Extends Offer Period for Tandberg Holders to Dec. 3
- Radian (RDN) Shares Rallying as CFO Says Nov. Delinquencies Were Less Than Expected
- Highlights From Staples' (SPLS) Q3 Conference Call: Corporate Express Integration on Track; Positive Consumer Traffic
- McGraw-Hill (MHP) Completes Sale of BusinessWeek to Bloomberg L.P.; To Recognize $9.3M Pre-Tax Gain
National Securities initiates coverage on Anadys Pharmaceuticals (Nasdaq: ANDS) with a Buy. Price target $5.
To see more analyst ratings on ANDS Click Here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
Related Categories
New CoverageStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
